𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Comparison of PathVysion and INFORM fluorescence in situ hybridization kits for assessment of HER-2/neu status in breast carcinoma

✍ Scribed by Kakar, S


Book ID
122326426
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2000
Tongue
English
Weight
990 KB
Volume
5
Category
Article
ISSN
1532-8619

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Comparison of HER-2 status determined by
✍ Yun Gong; Daniel J. Booser; Nour Sneige πŸ“‚ Article πŸ“… 2005 πŸ› John Wiley and Sons 🌐 English βš– 94 KB

## Abstract ## BACKGROUND Accurate assessment of __HER‐2__ status is necessary prior to anti‐__HER‐2__ antibody (trastuzumab) therapy for metastatic breast carcinoma. However, controversy exists regarding whether to assess __HER‐2__ status in the primary tumor or in metastatic lesions. It is also